CRSP

#1114
CRISPR Therapeutics AG - Common Shares
56.1 8 USD
-0.35%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
56.18
56.18
1年のレンジ
35.48
78.48
1日の変化
-0.35%
月次変化
+9.47%
6か月変化
+7.42%
1年の変化
+52.25%
以前の終値
56.3 8
Open
56.1 8
安値
56.1 8
High
56.1 8
ボリューム
132
チャート全体を表示 Full chart

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 5.42 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry 生物工学
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-8.11
売上高対価格比率
1 343.5

CRISPR Therapeutics AG - Common Shares

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

ニュース